August 09, 2021

Gilead Sciences Statement on Requiring Vaccination Against COVID-19 for Employees

Foster City, Calif., August 9, 2021 Gilead Sciences announced today that the company will require all employees and contractors to be fully vaccinated against COVID-19 as of October 1, 2021, where allowed by law and where vaccine supply is readily available. This includes all U.S. employees. In establishing this mandate, Gilead is building on the company’s long legacy as a leader in antiviral science and public health. By requiring vaccines, our goals are to safeguard the health of our workforce and to protect the patients we serve and the communities in which we live and work. This requirement also allows us to take a critically important step to protect our workplaces, helping to ensure the seamless delivery of our medicines for patients in need. 

In reaching this decision, we evaluated the increasing COVID-19 diagnoses in the United States and around the world and the effectiveness of vaccines in reducing infections, hospitalizations and deaths. We also have engaged our employees extensively on the issue of vaccination. For those employees with religious beliefs or medical conditions that prevent them from getting vaccinated, we will offer an appropriate accommodations review process. Where it is not possible or practical to mandate vaccination, the company will strongly recommend that employees get vaccinated. 

Gilead has led efforts to control COVID-19 since the earliest days of the pandemic – through the development and delivery of the first treatment for patients hospitalized with COVID-19, emergency funding for community organizations, and collaborations to better understand and mitigate health inequities highlighted during the pandemic.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

For more information about Gilead, please visit the company’s website at www.gilead.com, follow Gilead on Twitter (@Gilead Sciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

Investors

Jacquie Ross
investors_relations@gilead.com

Media Contact

Meaghan Smith
public_affairs@gilead.com